NCT00640588

Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine

Prospective Exploratory Study to Describe in CHB naïve and Non-naïve Patients, Hepatitis B Virus (HBV) Kinetics During the First 24 Weeks of Treatment With Telbivudine

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will explore HBV kinetics in CHB patients during the first 24 weeks of treatment with telbivudine

Conditions

• Hepatitis B, Chronic

Interventions

Type	Name	Description
DRUG	Telbivudine	Arm 1: 600 mg/day, oral telbivudina for 24 weeks
DRUG	oral adefovir	Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks

Timeline

• Start date: 2008-03-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2008-03-21
• Last updated: 2017-03-28

Locations

1 site across 1 country: Spain